SCHEMBL17237054

SCHEMBL17237054

COc1cc(C=Cc2cc(OC)c(OC)c(OC)c2)cc(NC=CC(=O)c2cc(OC)c(OC)c(OC)c2)c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.60
▸ GAA P10253 1/20 0.60
▸ TNFRSF1A P19438 6/20 0.59
▸ ABCG2 Q9UNQ0 2/20 0.58
▸ MEN1 O00255 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ GLA P06280 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ TUBB1 Q9H4B7 2/20 0.56
▸ ABCB1 P08183 2/20 0.54
▸ TUBB4A P04350 1/20 0.54
▸ TUBB P07437 1/20 0.54
▸ TUBA3C P0DPH7 1/20 0.54
▸ TUBA1B P68363 1/20 0.54
▸ TUBA4A P68366 1/20 0.54
▸ TUBB4B P68371 1/20 0.54
▸ TUBB3 Q13509 1/20 0.54
▸ TUBB2A Q13885 1/20 0.54
▸ TUBB8 Q3ZCM7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17237049 1.00 POLB (0.60) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17237238 0.93 TUBB1 (0.56) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17237235 0.93 TUBB1 (0.56) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17236767 0.92 TUBB1 (0.67) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17236764 0.92 TUBB1 (0.67) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17236659 0.92 POLB (0.54) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17236661 0.92 POLB (0.54) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17237341 0.92 TNFRSF1A (0.70) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17237344 0.92 TNFRSF1A (0.70) POLBGAATNFRSF1AABCG2MEN1
SCHEMBL17237059 0.92 MEN1 (0.62) POLBGAATNFRSF1AABCG2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP claimed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US claimed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US claimed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP claimed
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP disclosed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS MCL1, HCCS, CASP3 POLB 3581/4885GAA 3099/4885TNFRSF1A 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback